References
- Amin D K, Shah P K, Hulse S, Shellock F G, Swan H JC. Myocardial metabolic and hemodynamic effects of intravenous MDL 17043, a new cardiotonic drug, in patients with chronic severe heart failure. Am Heart J 1984; 108: 1285–1292
- Benotti J R, Grossman W, Braunwald E, Carabello B A. Effects of Amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circ 1980; 62: 28–34
- Braunwald E, Kloner R A. The stunned myocardium: prolonged postischemic ventricular dys-function. Circulation 1982; 66: 1146–1149
- Bristow M R, Ginsburg R, Minoke W. Decreasing catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982; 307: 205–211
- Crawford M H, Richards K L, Sodums M T, Kennedy G T. Positive inotropic and vasodilator effects of MDL 17043 in patients with reduced left ventricular performance. Am J Cardiol 1984; 53: 1051–1053
- Dage R C, Roebel L E, Hsieh C P, Weiner D L, Woodward J K. Cardiovascular properties of a new cardiotonic agent: MDL 17043. J Cardiovasc Pharmacol 1982; 4: 500–508
- Feldman M C, Copelas L, Gwathmey J K, Phillips P, Warren S E, Schoen F JO, Grossman W, Morgan J P. Deficient production of cAMP: pharma-cologic evidence of an important cause of contractile dysfunction in patients with end-stage failure. Circulation 1987; 75: 331–339
- Fowler M B, Laser J A, Hopkins G L, Minobe W, Bristow M R. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and sub-sensitivity to agonist response. Circulation 1986; 74: 1290–1302
- Gage J, Rutman H, Lucido D, LeJemtel T H. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 1986; 74: 865–876
- Gonzales M, Desager J P, Jaquemart J L, Chenu P, Muller T. Installe: Efficacy of enoximone in management of refractory low-output states following cardiac surgery. J Cardiothorac Anesth 1988; 2: 409–418
- Herrmann H C, Ruddy T D, Deo W, Strauss H W, Boucher C A, Fifer M A. Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analysis. JACC 1987; 9: 1117–1123
- Hines R. Clinical applications of Amrinone. J Cardiothorac Anesth 1989; 3: 24–32
- Kanter K R, Ruzevich S A, Pennington D G, McBride L R, Swartz M T, Willman V L. Follow-up of survivors of mechanical circulatory support. J Thorac Cardiovasc Surg 1988; 96: 72–80
- Kariya T, Willie L J, Dage R C. Biochemical studies on the mechanism of cardiotonic activity of MDL 17043: possible involvement of cyclic AMP phosphodiesterase inhibition. J Cardiovasc Pharmacol 1982; 4: 509–514
- Kereiakes D, Chatterjee K, Parmley W W, Atherton B, Curran D, Kereiakes A, Spangenberg R. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. JACC 1984; 4: 884–889
- Likoff M J, Ulrich S, Hakki A, Iskandrian A B. Comparison of acute hemodynamic response to doubutamine and intravenous MDL 17043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 1986; 57: 1328–1334
- Martin J L, Likoff M J, Janicki J S, Laskey W K, Hirshfeld J W, Weber K T. Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure. JACC 1984; 4: 875–883
- McGee M G, Zillgitt T L, Trono R, Turner S A, Davis G L, Fuqua J M, Edelman S K, Norman J C. Retrospective analysis of the need for mechanical circulatory support (intraaortic balloon pump/abdominal left ventricular assist device or partial artificil heart) after cardiopulmonary bypass: a 44 months study of 44168 patients. Am J Cardiol 1980; 46: 135–142
- Pae W E, Pierce W S, Pennock J L, Campell D B, Waldhausen J A. Long-term results of ventricular assist pumping in postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg 1987; 93: 434–441
- Roebel L E, Dage R C, Cheng H C, Woodward J K. Characterization of the cardiovascular activities of a new cardiotonic agent MDL 17043. J Cardiovasc Pharmacol 1982; 4: 721–729
- Roebel L E, Hodgeman R J, Velayo N L, Dage R C, Woodward J K. Effect of MDL 17043, a new cardiotonic agent, on myocardial oxygen consumption. J Pharm Pharmacol 1982; 35: 247–249
- Vincent J L, Carlier E, Berre J, Armistead C W, Jr., Kahn R J, Coussoert E, Cantraine F. Administration of enoximone in cardiogenic shock. Am J Cardiol 1988; 62: 419–423